A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HSK39297 Tablets in Patients With Lupus Nephritis
Latest Information Update: 02 Feb 2026
At a glance
- Drugs HSK 39297 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 02 Feb 2026 New trial record